FoxWayne Enterprises Acquisition in a regulatory filing said CEO Robb Knie loaned the SPAC $50,000. In addition, FoxWayne said several shareholders of the sponsor in April loaned $254,999 to the SPAC. The loans are interest-free and non-convertible.
FoxWayne raised $50 million in a January 2021 IPO to target a biotechnology or telemedicine company in North America. The SPAC terminated a deal with Aerami Therapeutics in March of this year, citing unfavvorable market conditions.
FoxWayne shareholders are expected to vote next month on whether to grand an extension of up to six months beyond the current July 22 deadline. Read more.
